Insmed (INSM) to Release Quarterly Earnings on Thursday

Insmed (NASDAQ:INSM) is expected to be posting its Q4 2025 results before the market opens on Thursday, February 19th. Analysts expect Insmed to post earnings of ($1.25) per share and revenue of $263.9660 million for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 8:00 AM ET.

Insmed Trading Down 0.1%

Shares of Insmed stock opened at $148.43 on Thursday. The company has a market capitalization of $31.66 billion, a P/E ratio of -23.98 and a beta of 1.11. The stock has a fifty day simple moving average of $171.34 and a 200 day simple moving average of $161.28. Insmed has a 12-month low of $60.40 and a 12-month high of $212.75. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on INSM shares. Wells Fargo & Company set a $195.00 target price on shares of Insmed in a report on Thursday, December 18th. Barclays assumed coverage on shares of Insmed in a research report on Tuesday, January 27th. They issued an “overweight” rating and a $231.00 price objective for the company. The Goldman Sachs Group lifted their target price on shares of Insmed from $225.00 to $258.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Morgan Stanley upped their target price on Insmed from $157.00 to $162.00 and gave the company an “equal weight” rating in a report on Friday, January 30th. Finally, Jefferies Financial Group set a $269.00 price target on Insmed in a report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Insmed has an average rating of “Buy” and an average price target of $204.24.

Insider Activity

In other Insmed news, CFO Sara Bonstein sold 748 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $156.34, for a total value of $116,942.32. Following the sale, the chief financial officer directly owned 79,758 shares in the company, valued at $12,469,365.72. This represents a 0.93% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Roger Adsett sold 791 shares of the business’s stock in a transaction on Tuesday, February 3rd. The shares were sold at an average price of $156.17, for a total transaction of $123,530.47. Following the transaction, the chief operating officer owned 106,810 shares of the company’s stock, valued at $16,680,517.70. This trade represents a 0.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 258,253 shares of company stock worth $46,281,042. Insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in INSM. Duquesne Family Office LLC raised its stake in Insmed by 3.0% in the third quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock valued at $348,999,000 after purchasing an additional 70,000 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Insmed by 5.7% in the 3rd quarter. Invesco Ltd. now owns 2,003,871 shares of the biopharmaceutical company’s stock worth $288,577,000 after buying an additional 107,538 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Insmed by 42.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 1,544,315 shares of the biopharmaceutical company’s stock valued at $222,397,000 after buying an additional 462,265 shares in the last quarter. Orbis Allan Gray Ltd bought a new stake in shares of Insmed during the 2nd quarter worth $153,389,000. Finally, Northern Trust Corp lifted its holdings in shares of Insmed by 10.6% during the 3rd quarter. Northern Trust Corp now owns 1,072,942 shares of the biopharmaceutical company’s stock worth $154,514,000 after acquiring an additional 103,142 shares during the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.